Articles tagged with Brain Tumors
A Korean research team developed a patient-specific blood-brain tumor barrier-on-a-chip model to predict individual responses to glioblastoma therapies. The chip recreates a patient's own tumor cells together with the surrounding peritumoral vascular environment, allowing for precise predictions of treatment responses.
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
A KAIST research team identified a previously unrecognized immune mechanism through which anti-CTLA-4 promotes B-cell responses in tumor-draining lymph nodes. This response is critical for the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors like glioblastoma.
Researchers at UT MD Anderson Cancer Center have achieved high response rates in patients with hard-to-treat acute myeloid leukemia (AML) using an all-oral combination therapy. The study also provides insights into the origins of cancer, revealing that tumors evolve rapidly through bursts of genetic changes.
A new study published in JAMA Network Open found that removing olfactory groove meningioma may improve blood sugar control and weight in some patients with diabetes. The research team tracked long-term changes in hemoglobin A1c levels after tumor removal surgery.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
A Capital Medical University study reveals that intraoperative signal changes can predict vision loss during brain tumor surgery. Researchers found that a specific signal component, N75-P100, is strongly associated with postoperative visual outcomes.
A new study finds that testosterone slows the growth of glioblastoma in men, contrary to its usual effect on tumors. Blocking testosterone makes tumors grow faster in both male and female patients.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
A study found that HSP90B1 upregulates in gliomas and correlates with poor prognosis and tumor malignancy. It enhances tumor cell proliferation, migration, and invasion while protecting cells from radiotherapy-induced apoptosis by modulating DNA damage repair factors.
Researchers at St. Jude Children's Research Hospital developed patient-derived tumor organoids that accurately reflect the biologic underpinnings of embryonal brain tumors. The models enable faster functional assays and preclinical drug testing without relying on newly obtained tumor samples, advancing the study of pediatric brain tumors.
The study reveals that ZFTA-RELA exploits open regions of the genome to trap immature brain cells in developmental limbo. This finding may lead to novel therapeutic strategies to test, such as forcing cells past immature developmental states.
New research reveals that tumor cells in supratentorial ependymomas cluster into distinct neighborhoods, each with a specific role, such as proliferating or invading. Understanding these cell subtypes could help predict treatment response and inform targeted therapies for this aggressive childhood brain cancer.
Researchers found a set of light-sensing genes essential to pineoblastoma formation in the developing pineal gland. They extended the finding to medulloblastoma and retinoblastoma, indicating a common developmental state and potential shared therapeutic dependency.
Researchers at the University of Southern California Health Sciences have discovered a new treatment approach that combines laser heat therapy with immunotherapy to improve survival rates for patients with high-grade astrocytoma. Nearly half of patients treated with this combination were still alive after 18 months, exceeding the typic...
Researchers have discovered a way to enhance awake brain mapping, allowing neurosurgeons to remove more cancerous tissue while minimizing disruptions to patients' quality of life. The new technique uses subtle changes in patient behavior to inform surgical decisions.
A Phase 3 trial found stereotactic radiation targeting individual tumors improved symptom burden, cognitive outcomes, and daily function compared to whole brain radiation. Patients managed with stereotactic radiation also displayed better performance status and could remain more independent with everyday activities.
A new AI-powered algorithm, M-PACT, uses liquid biopsy to classify pediatric brain tumors based on DNA methylation patterns. The technology has been shown to achieve a high sensitivity rate of 92% in identifying brain tumors.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
The Rice Brain Institute has awarded seed grants to four collaborative projects that unite Rice faculty with clinicians and scientists across the Texas Medical Center. The grants support innovative research in brain science, mental health, and neurological disease.
Researchers found that reactivating and maintaining p53 using idasantulin and selinexor significantly extended survival in ATRT and MRT mouse models, reducing tumor burden and increasing survival rates. The study's findings provide a strong rationale for investigating this treatment approach for rhabdoid tumors.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
Researchers have identified two proteins that allow cancer cells to evade destruction by brain immune cells, known as microglia. By removing these proteins, microglia play a key role in eliminating cancer cells during the early stage of their arrival in the brain.
Researchers at Mass General Brigham developed a modified herpes simplex virus that stimulates the immune system to attack glioblastoma cells, increasing T-cell and natural killer cell responses. The virus, engineered to recognize markers found on glioblastoma cells, also increases overall survival in preclinical models.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
Researchers at MD Anderson have discovered bacterial genetic and cellular elements within brain tumor cells, potentially influencing tumor behavior. Inflammation may also drive the earliest stages of lung cancer, with targeting proinflammatory pathways emerging as a potential early intervention approach
A new study found that disrupted brain fluid circulation, even in regions far from the tumor, can forecast poorer survival rates in glioblastoma patients. The researchers used MRI scans to measure fluid movement and accumulation, revealing a link between impaired glymphatic function and shorter survival.
Researchers analyzed 29 new and 22 previously reported cases of PCNSL involving the ventricles, finding different clinical symptoms such as headache, dizziness, and vision impairment. The study suggests that despite its unusual location, ventricular PCNSL behaves like other forms of brain lymphoma, with a recommended treatment strategy...
A recent UK study has highlighted the need for equitable investment and adoption of new innovations in brain tumor care. The research team found that genomic testing has expanded rapidly but many services are struggling to keep pace, leading to regional inequalities in access to advanced treatments.
The study identified two major factors that improve survival for children with IHG: achieving a complete surgical resection and cancer-directed adjuvant treatment. Early surgery in infants was fraught with risks of bleeding and early oncologic death, highlighting the need for strategies to minimize surgical morbidity.
Researchers studied clinical features and treatment strategies for managing postoperative space-occupying cysts in brain tumor surgical sites. External drainage using an Ommaya reservoir or direct percutaneous puncture drainage showed favorable results, reducing cyst size and improving patient outcomes.
Researchers have discovered a previously overlooked brain tumor subtype with strong immune activity but poorer survival rates. An AI framework has been developed to assist doctors in accurately identifying this subtype, enabling more personalized patient care.
A Harvard Medical School-led research team developed an AI tool called PICTURE that can reliably tell apart glioblastoma and primary central nervous system lymphoma during surgery. The tool distinguishes between the two cancers with near-perfect accuracy, reducing errors in diagnosis and guiding critical treatment decisions.
Researchers from Korea University mapped the evolutionary trajectory of meningiomas at single-cell resolution, revealing profound shifts in proliferative programs and tumor–immune interactions. The study identified COL6A3 as a central player driving recurrence and treatment resistance.
A recent study by Mass General Brigham researchers found that adults with a history of moderate-to-severe traumatic brain injuries are at a higher risk of developing malignant brain tumors. The study evaluated data from over 75,000 people and discovered a significant association between TBI and increased tumor development.
Researchers identified a key metric, acoustic emission dose, to adjust ultrasound power and open the blood-brain barrier for delivering drugs in patients with high-grade gliomas. This allows for reliable treatment of brain cancer by bypassing the protective blood-brain barrier.
A European study analyzed data from over 30,000 children with brain tumors, providing a clear overview of their survival outcomes. The study found that differences in survival rates between countries are smaller than previously thought, suggesting improved access to similar treatments across Europe.
Researchers compared CECS and EES techniques for treating giant and irregular pituitary tumors. The study found that CECS resulted in a higher gross tumor removal rate (66%) and lower postoperative bleeding rates compared to EES.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Researchers found that 2.7% of 70-year-old women had meningiomas, a type of tumor on the meninges outside the brain tissue. The study emphasizes the importance of diligence and careful consideration in managing these tumors, which are often benign and grow slowly.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
Researchers at Texas A">&M found that dogs with meningiomas live longer with radiation therapy than surgery. Radiation nearly doubles average survival time in dogs with brain tumors, while surgery had an average of about 10 months.
Researchers at Michigan Medicine have created nanodiscs that can target cholesterol levels in glioblastoma, starving cancer cells and increasing survival rates of treated mice. The combined treatment with radiation therapy was able to preserve normal brain structure and elicited an immunological memory.
Researchers discovered a novel line of communication between metastatic medulloblastoma and leptomeningeal fibroblasts, facilitating recruitment and reprogramming to support tumor growth. Disrupting this communication may offer a potential treatment opportunity for this devastating disease.
Researchers have found that targeting PGM3 can help stop the growth of glioblastoma, a fast-growing brain tumor. By blocking this enzyme, tumors can be effectively suppressed.
Scientists at St. Jude Children's Research Hospital discovered FOXR2 activation in multiple pediatric CNS tumor types, including high-grade gliomas and pineoblastomas, with significantly different clinical outcomes. The study highlights the importance of combining molecular findings with other diagnostic approaches to improve treatment...
The Ralph L. Sacco Scholarships in Brain Health support research into vascular disease's impact on cognitive decline, dementia, and brain health. Researchers Hortense Triniac and Katy Walsh will study protein interactions to reduce stroke risk and investigate cerebral amyloid angiopathy.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
Recent research reveals that avapritinib, a PDGFRA inhibitor, demonstrates potent activity against pediatric high-grade glioma tumors with PDGFRA alterations. Clinical trials in patients showed an initial clinical response and improved survival rates, suggesting the potential for avapritinib as a therapeutic option.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers identified the prion protein as a key player in the progression of glioblastoma, a type of brain tumor. The study found that blocking the production of this protein using genetic editing reduced the ability of tumor stem cells to proliferate and invade tissues.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers found that avapritinib decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma. The drug targets the PDGFRA gene, which is commonly mutated in this type of cancer.
Researchers developed a new technique to identify aggressive medulloblastoma in children, allowing doctors to tailor treatments and reduce unnecessary side effects. The MYC test can be performed in any pathology lab worldwide, providing faster and more accurate care for young patients with brain tumours.
A new study by Mass General Brigham researchers has found a link between genetic mutations and toxin exposure in firefighters' brain tumors. The study identified a unique pattern of genetic mutations, known as a mutational signature, in many firefighter samples, especially those who had spent more years firefighting.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.